Skip to Main Content

Monthly Archives: September 2016

09.29.16

O’Neill Institute Hosts Meeting to discuss improving Hepatitis C data collection and surveillance

By Sonia Canzater

On September 19th, the Hepatitis C Policy Project hosted a meeting at the Georgetown University Law Center in Washington, DC to discuss strategies to improve data collection and case surveillance for Hepatitis C in the United States. Thought leaders from a range of public health backgrounds, – including physicians, patient advocates, researchers and federal agency directors […]

Thematic Areas:

09.29.16

O'Neill Institute Hosts Meeting to discuss improving Hepatitis C data collection and surveillance

By Sonia Canzater

On September 19th, the Hepatitis C Policy Project hosted a meeting at the Georgetown University Law Center in Washington, DC to discuss strategies to improve data collection and case surveillance for Hepatitis C in the United States. Thought leaders from a range of public health backgrounds, – including physicians, patient advocates, researchers and federal agency directors […]

Thematic Areas:

09.24.16

India’s Surrogacy Debate

By Rebecca Reingold

India has emerged as the world’s “surrogacy hub”. Infertile couples and, increasingly, gay couples and single women from different countries are paying Indian women to carry their embryos through to birth. While the surrogacy industry in India is extremely lucrative (worth more than $2.3 billion per year), the government has failed to regulate the practice since it became […]

Thematic Areas:

09.24.16

India's Surrogacy Debate

By Rebecca Reingold

India has emerged as the world’s “surrogacy hub”. Infertile couples and, increasingly, gay couples and single women from different countries are paying Indian women to carry their embryos through to birth. While the surrogacy industry in India is extremely lucrative (worth more than $2.3 billion per year), the government has failed to regulate the practice since it became […]

Thematic Areas:

09.19.16

More sugar industry interference: this time with ads warning of the health effects of soda

By Sarah Roache

Last week, we learned that the sugar industry paid Harvard scientists to minimize the link between sugar and heart disease, blaming saturated fat instead. Unfortunately, scientific evidence isn’t the only thing the industry has been influencing: a soda company in Colombia has successfully pushed for the suspension of a television advertisement warning the public about […]

Thematic Areas:

09.15.16

New Report Highlights State Policy Options for Promoting Prescription Drug Access

By O’Neill Institute

This post was written by Katie Keith, Adjunct Professor at Georgetown Law. Any questions about this post should be directed to Katie.Keith@georgetown.edu. Controversy around the more than 400 percent increase in the price of EpiPens is just the latest in a year filled with stories of dramatic drug price gouging. Indeed, health headlines have been […]

Categories:
Tags:
Thematic Areas:

09.14.16

The Wild, Wild West of Stem Cell Regulation and the Lessons of History

By O’Neill Institute

This post was written by Andrew Hennessy-Strahs, a 2017 Global Health Law LL.M. Candidate at Georgetown University Law Center. Any questions or comments can be directed to adh75@georgetown.edu. September 14, 2016 marks the twenty-six year anniversary of the first successful human gene therapy in the world. Doctors in the National Institute of Health, in Bethesda […]

Categories:
Thematic Areas:

09.12.16

Climate Change: A Growing Threat to Our Health

By O’Neill Institute

This post was written by Lawrence O. Gostin, Faculty Director of the O’Neill Institute for National and Global Health Law and University Professor. Any questions about this post should be directed to gostin@law.georgetown.edu. A scientific consensus exists that climate change is anthropogenically forced, with impacts on ecological systems and human health already in evidence. The […]

Categories:
Thematic Areas:

09.09.16

The Exorbitant Pricing of Pharmaceuticals is in the News. Again.

By Katie Gottschalk

This week the pharmaceutical pricing discussion centers on Mylan, and its 548% boost in the price of EpiPens. The press coverage and industry promises are a familiar scene: a large drug company buys a well-established medication or technology, and then raises the price. There is outrage, there are statements of promises and remedies, and then […]

Tags:
Thematic Areas:

The views reflected in this expert column are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.